PEI-Genesis Promotes Peter Austin to EVP and Chief Operating Officer
6.5.2020 14:01:00 EEST | Business Wire | Press release
As companies around the world look to their next phase of operations in an ever-changing world, PEI-Genesis, a global leader in the design and assembly of custom engineered connectors and cable solutions, has promoted Peter Austin to Executive Vice President and Chief Operating Officer (COO), effective immediately, as announced today by Steven Fisher, the company’s president and CEO.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200506005046/en/
Peter Austin is named Executive Vice President and COO of PEI-Genesis, a Philadelphia-based global leader in the design and assembly of custom engineered connectors and cable solutions. (Photo: Business Wire)
“Peter started with PEI-Genesis in 2016, and I have come to respect his strategic thinking, relying on him as a trusted advisor,” said Fisher. “We’ll work closely together to develop our global strategy, and he will be responsible for its day-to day execution.”
Austin’s new role will include partnering with Fisher to create comprehensive plans to meet the company’s performance objectives, plan for the strengthening of the business after the current pandemic, and to maintain the company’s I CARE values.
“It’s an honor to be named COO at a company like PEI-Genesis, which has been an integral part of this industry for generations,” said Austin. “Working with Steven and the senior team has proven an excellent match, and I look forward to growing and expanding, even as we navigate these uncharted waters.”
Reporting to Austin will be Jonathan Parry, Senior VP and Managing Director of Europe, Alex Tsui, Managing Director of Asia, and John Rozanski, Senior Director of Global Strategic Accounts. Austin will also continue in his role as General Manager of North America.
“With Peter firmly in place as COO, I will focus my efforts on other strategic needs, including enhanced relationships with suppliers and the continuing evolution of the company,” said Fisher. “In times like these, leadership is critical in our evolution, and there is no one I trust more by my side than Peter.”
Austin joined PEI-Genesis with over 20 years in the electronics industry. Prior to 2016, he has worked as Vice President of Global Sales & Marketing at NXP Semiconductors and prior to that, served as Director of Global Business Management at National Semiconductor where he oversaw the company’s product portfolio. Austin also spent 13 years with Future Electronics in various roles including Director and Worldwide Business Manager, Corporate Product Marketing.
About PEI-Genesis
PEI-Genesis is one of the world’s fastest assemblers of precision connectors and cable assemblies. From the largest connector component inventory in the world, they develop engineered solutions that support the military, industrial, medical, aerospace, transportation, and energy sectors worldwide. Headquartered in Philadelphia, PA, PEI-Genesis has production facilities in South Bend, IN; Chandler, AZ; Southampton, UK; and Zhuhai, China as well as sales offices throughout the Americas, Europe and Asia. More information may be found at www.peigenesis.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200506005046/en/
Contact information
Media contacts:
Jenna Hinkle
215.737.1151
Jenna.Hinkle@peigenesis.com
Debbie Albert
215.283-6006
debbie@albertcommunications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 13:00:00 EET | Press release
Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022786567/en/ David Weinreich, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck "For people living with TGCT, the impact of the disease is often felt through persis
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 12:30:00 EET | Press release
WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural world, the collection introduces a newly developed system of WHOOP bands, Italian technical apparel, outerwear, and accessories designed to move between urban and outdoor settings. Performance extends be
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 12:28:00 EET | Press release
Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums bleeding when brushing can happen to any of us. When they do, it shouldn't be ignored," said Eva Castro Perea, who holds a degree in dentistry
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greatest difference between treatment groups was observed at Week 6 (adjusted mean difference, −1.14 points; p=0.0488).
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom